Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

Foxconn invests US$30 million in Robocore to expand into elderly care robotics market

Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO

Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial

According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million

Alkem launches ceramide-boosting moisturizing lotion for skin barrier repair

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

The projected business potential is around US$ 1 million in the first year

European Commission grants approval of Ogsiveo

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors

Shanmuga Hospital commissions advanced PH impedance and manometry system

This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.

Merck and mantro launch EdiMembre to transform alternative protein industry

Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent